PE20201167A1 - Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados - Google Patents

Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados

Info

Publication number
PE20201167A1
PE20201167A1 PE2020000381A PE2020000381A PE20201167A1 PE 20201167 A1 PE20201167 A1 PE 20201167A1 PE 2020000381 A PE2020000381 A PE 2020000381A PE 2020000381 A PE2020000381 A PE 2020000381A PE 20201167 A1 PE20201167 A1 PE 20201167A1
Authority
PE
Peru
Prior art keywords
solution
interest
methods
viruses
biological product
Prior art date
Application number
PE2020000381A
Other languages
English (en)
Inventor
Shengjiang Liu
Allison Titong
Wensheng Wang
Nicholas Spadoni
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20201167A1 publication Critical patent/PE20201167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A01N37/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta divulgacion se refiere a metodos para usar en la inactivacion de virus. Los metodos de inactivacion de virus con N-metilglucamidas son aplicables al proceso de purificacion de medicamentos biologicamente activos como subunidades de proteinas, proteinas (enzimas, factores, etc.), proteinas recombinantes, anticuerpos, vacunas o productos terapeuticos geneticos. Los detergentes utilizados en este metodo se basan en multiples homologos de N-metilglucamida, que consisten en un resto de glucosa hidrofilica y una cola de acido graso hidrofobico, unidos por un enlace amida. Ademas, estos detergentes a base de azucar son no ionicos por naturaleza, lo que no interrumpe la proteina del farmaco, los productos biologicos del plasma, la vacuna viral sin envoltura, o las particulas virales adenoasociadas. Un metodo para purificar una solucion de un producto biologico de interes que tiene un contaminante de virus envuelto no identificado, que incluye incubar una solucion de producto biologico de interes con una solucion estandar, inactivando cualquier posible contaminante de virus envuelto presente en la solucion de la etapa (a), midiendo el virus inactivado presente en la solucion final de la etapa (b), incubando una solucion de producto biologico separado de interes, con una solucion de N-metilglucamida, midiendo el virus inactivado presente en la solucion final de la etapa (d), y comparando los resultados de la solucion final con las soluciones de la etapa (c) y la etapa (e).
PE2020000381A 2017-09-18 2018-09-12 Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados PE20201167A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559812P 2017-09-18 2017-09-18
PCT/US2018/050579 WO2019055463A1 (en) 2017-09-18 2018-09-12 METHODS OF INACTIVATING VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES

Publications (1)

Publication Number Publication Date
PE20201167A1 true PE20201167A1 (es) 2020-10-28

Family

ID=63762999

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000381A PE20201167A1 (es) 2017-09-18 2018-09-12 Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados

Country Status (14)

Country Link
US (3) US11564392B2 (es)
EP (1) EP3684921A1 (es)
JP (2) JP7317005B2 (es)
KR (1) KR20200052370A (es)
CN (1) CN111108193A (es)
AU (1) AU2018331357A1 (es)
BR (1) BR112020005229A2 (es)
CA (1) CA3075853A1 (es)
IL (1) IL273229A (es)
MX (1) MX2020002939A (es)
PE (1) PE20201167A1 (es)
SG (1) SG11202002449PA (es)
TW (1) TWI834623B (es)
WO (1) WO2019055463A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI834623B (zh) * 2017-09-18 2024-03-11 美商拜耳保健有限責任公司 使用n-甲基葡糖醯胺及其衍生物以使病毒去活化之方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
DE4103800A1 (de) 1990-09-27 1992-04-02 Helmuth Schmoock Folie
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
US5695928A (en) 1993-12-10 1997-12-09 Novartis Corporation Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction
DE19528221C2 (de) 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
CA2175719A1 (en) 1996-05-03 1997-11-04 Brian J. Underdown Compositions and methods for protection against immunologically diverse isolates of influenza virus
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
CN1192766C (zh) 1998-10-23 2005-03-16 伊迪亚股份公司 开发、测试和使用用于改进的有效负载和可控制性解缔/缔合速度的大分子和复合聚集体的缔合物的方法
US20020127587A1 (en) 2001-02-13 2002-09-12 Domenica Simms Methods and compositions for isolation of biological macromolecules
KR20070108284A (ko) 2003-10-28 2007-11-08 가부시끼가이샤 센단세메이가가꾸겐큐죠 Ｃ형 간염 바이러스의 검출 방법
JP4131850B2 (ja) 2003-12-04 2008-08-13 アークレイ株式会社 インフルエンザウイルスの免疫学的測定方法
ATE493659T1 (de) 2004-05-19 2011-01-15 Advanced Life Science Inst Inc Verfahren zum nachweis von hepatitis-b-virus
WO2006033368A1 (ja) 2004-09-22 2006-03-30 Advanced Life Science Institute, Inc. Ｂ型肝炎ウイルスｓ抗原の検出法
WO2008076371A2 (en) * 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
CA2766173A1 (en) * 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
CN101081298A (zh) * 2007-06-26 2007-12-05 陈少莺 一种猪伪狂犬病新型亚单位疫苗制备方法
EP2280690A2 (en) * 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
WO2009131995A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
WO2010014903A1 (en) 2008-07-31 2010-02-04 Massachusetts Institute Of Technology Multiplexed olfactory receptor-based microsurface plasmon polariton detector
JP2010077091A (ja) 2008-09-26 2010-04-08 Beacle Inc Ｂ型肝炎ウイルスタンパク質中空バイオナノ粒子とリポソームを用いたｓｉＲＮＡの内包と細胞選択的なｓｉＲＮＡの導入方法
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
SI3043814T1 (sl) 2013-09-13 2021-04-30 Salipro Biotech AB, Greenhouse Labs Antigen in postopek za proizvodnjo le-tega
CN105722523B (zh) 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
JP2016182112A (ja) 2015-03-25 2016-10-20 東ソー株式会社 ウイルスからの核酸抽出試薬
TWI834623B (zh) * 2017-09-18 2024-03-11 美商拜耳保健有限責任公司 使用n-甲基葡糖醯胺及其衍生物以使病毒去活化之方法

Also Published As

Publication number Publication date
BR112020005229A2 (pt) 2020-09-24
MX2020002939A (es) 2020-07-22
US20240196891A1 (en) 2024-06-20
RU2020113752A3 (es) 2022-04-22
EP3684921A1 (en) 2020-07-29
SG11202002449PA (en) 2020-04-29
AU2018331357A1 (en) 2020-04-02
CN111108193A (zh) 2020-05-05
US11564392B2 (en) 2023-01-31
WO2019055463A1 (en) 2019-03-21
KR20200052370A (ko) 2020-05-14
JP2023139096A (ja) 2023-10-03
CA3075853A1 (en) 2019-03-21
US20230143494A1 (en) 2023-05-11
TW201925163A (zh) 2019-07-01
IL273229A (en) 2020-04-30
RU2020113752A (ru) 2021-10-20
US20200260727A1 (en) 2020-08-20
JP7317005B2 (ja) 2023-07-28
JP2020533987A (ja) 2020-11-26
TWI834623B (zh) 2024-03-11

Similar Documents

Publication Publication Date Title
Perng et al. ISG15 in antiviral immunity and beyond
ES2950887T3 (es) Purificación del Virus Zika
Rajsbaum et al. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response
Cheong et al. Influenza A virus NS1 protein inhibits the NLRP3 inflammasome
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
CY1124689T1 (el) Trans-αντιγραφοymeno rna
CL2018002825A1 (es) Vacuna contra vrs
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
CL2013003248A1 (es) Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
BR112015022790A8 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
Kwon et al. An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
Komarova et al. Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
Kell et al. RIG-I-like receptor activation drives type I IFN and antiviral signaling to limit Hantaan orthohantavirus replication
ES2980846T3 (es) Purificación de proteínas e inactivación de virus con alquilglucósidos
El-Sayed et al. Sero-prevalence of avian influenza in animals and human in Egypt.
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
Zhang et al. FAT10 is critical in influenza A virus replication by inhibiting type I IFN
Si et al. Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity
PE20201167A1 (es) Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados
Guo et al. DEF cell-derived exosomal miR-148a-5p promotes DTMUV replication by negative regulating TLR3 expression